Eli Lilly and Company (LLY)
Is Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes alive.
Pharmaceuticals Industry Analysis: Eli Lilly Tops My Tier Two
I invest for long-term total return, focusing on high-quality, dividend-paying industry leaders with strong financials and consistent performance. Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in pharmaceuticals, especially as AI could boost efficiency and profits. My tier-two pharma picks show solid fundamentals, but Eli Lilly stands out for its growth potential, especially in diabetes and weight loss drugs.
Lilly Stock Down 5% This Month: Should You Buy the Dip?
Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.
3 Fantastic Growth Stocks to Buy in August
We're well into the home stretch of 2025. August is more than halfway over.
Eli Lilly: Don't Bet Against This Biotech Powerhouse
Eli Lilly's recent 20% pullback is a buy-the-dip opportunity, as the market overreacted to mixed Orforglipron results. Blockbuster drugs Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% year-over-year, with raised FY2025 guidance. LLY's strategic R&D investments and acquisitions strengthen its innovation pipeline, supporting future growth and product diversification.
Novo Nordisk Stock Could Benefit From Eli Lilly's Weight-Loss Price Hikes
The pricing of weight-loss drugs like Lilly's Zepbound and Novo's Wegovy is a pressure point for investors.
Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.
Eli Lilly to hike UK price of weight-loss drug Mounjaro
Eli Lilly and Co (NYSE:LLY) will raise the UK list price of its weight-loss injection Mounjaro by up to 170% from September, increasing the cost of a month's supply of the highest dose from £122 to £330. The move follows US President Donald Trump's calls for drugmakers to raise prices in Europe to help lower costs for American patients.
Eli Lilly raises price of diabetes drug Mounjaro in UK ahead of Trump deadline
Dr. Kavita Patel, NBC News & MSNBC medical contributor, joins 'Fast Money' to talk Eli Lilly raising Mounjaro prices.
Guidance Watch: 2 Companies Bullishly Raising Forecasts
One company remains at the forefront of the AI frenzy, whereas the other has seen insiders dive in post-earnings.
Eli Lilly said it is in talks to raise drug prices in Europe, starting with weight-loss drug Mounjaro in the U.K., so it can meet President Trump's goal of bringing down prices in the U.S.
The move is part of the company's plan to renegotiate drug prices across other developed nations
Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks?
Healthcare has been one of the toughest sectors for investors over the past year. In fact, over the last 12 months, it has been the worst performing sector in the entire market.
